Roche

FY Revenues: 61.5 billion CHF (+8%)

FY Earnings: 14.1 billion CHF (+30%)

Comments: Pharmaceuticals Division sales were up 11% to CHF 48.5 billion, driven by recently launched products led by multiple sclerosis medicine Ocrevus, the new haemophilia medicine, Hemlibra and cancer medicines Tecentriq and Perjeta, offsetting the impact of competition from biosimilars for MabThera/Rituxan and Herceptin in Europe and Japan (decline combined CHF 1.2 billion) and MabThera/Rituxan, Herceptin and Avastin in the U.S. (estimated decline CHF 0.3 billion). Diagnostics Division sales increased 3% to CHF 12.9 billion. In December, Roche completed the $4.3 billion acquisition of Spark Therapeutics.